Compare Aon PLC (AON) vs Heron Therapeutics Inc (HRTX) Price & Performance

AON trades at $358.3, down 0.68% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates with $3.81 versus $3.8 expected, driven by 5% organic revenue growth. Valuation metrics include a P/E of 19.75 and P/S of 4.39, while profitability remains robust with a net income margin of 22.27% and ROE of 44.88%. Recent news highlights institutional buying and a new executive appointment.

The outlook is positive with a consensus price target of $410, implying 14% upside, supported by earnings momentum and solid cash flow. Risks include premium valuation concerns and modest organic growth. Analyst sentiment is balanced with 47% buy ratings, but high debt levels and competitive pressures warrant caution for investors.

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.